Corporate Profile
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using the company’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
The company’s first compound, STK-001 is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease.
The company is pursuing treatment for a second haploinsufficient disease, autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting the company’s belief in the broad potential for its proprietary approach.
Press Releases
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 17, 2024
BEDFORD, Mass. --(BUSINESS WIRE)--May 17, 2024-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated t ...Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 6, 2024
– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential ...Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
April 29, 2024
– Mr. Leggett brings more than two decades of experience as an investment banker and corporate executive leading financial st ...Corporate Presentation
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines.
